Top

Osteoporosis International

Published in:

18-08-2022 | Osteoporosis | Review

Role of Wnt signaling and sclerostin in bone and as therapeutic targets in skeletal disorders

Authors: Francesca Marini, Francesca Giusti, Gaia Palmini, Maria Luisa Brandi

Published in: Osteoporosis International | Issue 2/2023

Abstract

Summary

Wnt signaling and its bone tissue–specific inhibitor sclerostin are key regulators of bone homeostasis. The therapeutic potential of anti-sclerostin antibodies (Scl-Abs), for bone mass recovery and fragility fracture prevention in low bone mass phenotypes, has been supported by animal studies. The Scl-Ab romosozumab is currently used for osteoporosis treatment.

Introduction

Wnt signaling is a key regulator of skeletal development and homeostasis; germinal mutations affecting genes encoding components, inhibitors, and enhancers of the Wnt pathways were shown to be responsible for the development of rare congenital metabolic bone disorders. Sclerostin is a bone tissue–specific inhibitor of the Wnt/β-catenin pathway, secreted by osteocytes, negatively regulating osteogenic differentiation and bone formation, and promoting osteoclastogenesis and bone resorption.

Purpose and methods

Here, we reviewed current knowledge on the role of sclerostin and Wnt pathways in bone metabolism and skeletal disorders, and on the state of the art of therapy with sclerostin-neutralizing antibodies in low-bone-mass diseases.

Results

Various in vivo studies on animal models of human low-bone-mass diseases showed that targeting sclerostin to recover bone mass, restore bone strength, and prevent fragility fracture was safe and effective in osteoporosis, osteogenesis imperfecta, and osteoporosis pseudoglioma. Currently, only treatment with romosozumab, a humanized monoclonal anti-sclerostin antibody, has been approved in human clinical practice for the treatment of osteoporosis, showing a valuable capability to increase BMD at various skeletal sites and reduce the occurrence of new vertebral, non-vertebral, and hip fragility fractures in treated male and female osteoporotic patients.

Conclusions

Preclinical studies demonstrated safety and efficacy of therapy with anti-sclerostin monoclonal antibodies in the preservation/restoration of bone mass and prevention of fragility fractures in low-bone-mass clinical phenotypes, other than osteoporosis, to be validated by clinical studies for their approved translation into prevalent clinical practice.

Saito-Diaz K, Chen TW, Wang X, Thorne CA, Wallace HA, Page-McCaw A, Lee E (2013) The way Wnt works: components and mechanism. Growth Factors 31(1):1–31. https://doi.org/10.3109/08977CrossRef

Chen C, Zhao M, Tian A, Zhang X, Yao Z, Ma X (2015) Aberrant activation of Wntbeta-catenin signaling drives proliferation of bone sarcoma cells. Oncotarget 6(19):17570–83. https://doi.org/10.18632/oncotarget.4100.194.2012.752737CrossRef

Maeda K, Kobayashi Y, Koide M, Uehara S, Okamoto M, Ishihara A, Kayama T, Saito M, Marumo K (2019) The regulation of bone metabolism and disorders by Wnt signaling. Int J Mol Sci 20(22):5525. https://doi.org/10.3390/ijms20225525CrossRef

Duan P, Bonewald LF (2016) The role of the wnt/beta-catenin signaling pathway in formation and maintenance of bone and teeth. Int J Biochem Cell Biol 77(PtA):23–29. https://doi.org/10.1016/j.biocel.2016.05.015CrossRef

Jiang X, Charlat O, Zamponi R, Yang Y, Cong F (2015) Dishevelled promotes Wnt receptor degradation through recruitment of ZNRF3/RNF43 E3 ubiquitin ligases. Mol Cell 58(3):522–533. https://doi.org/10.1016/j.molcel.2015.03.015CrossRef

Manolagas SC (2000) Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 21(2):115–137. https://doi.org/10.1210/edrv.21.2.0395CrossRef

Wan Y, Lu C, Cao J, Zhou R, Yao Y, Yu J, Zhang L, Zhao H, Li H, Zhao J, Zhu X, He L, Liu Y, Yao Z, Yang X, Guo X (2013) Osteoblastic Wnts differentially regulate bone remodeling and the maintenance of bone marrow mesenchymal stem cells. Bone 55(1):258–267. https://doi.org/10.1016/j.bone.2012.12.052CrossRef

Lu C, Wan Y, Cao J, Zhu X, Yu J, Zhou R, Yao Y, Zhang L, Zhao H, Li H, Zhao J, He L, Ma G, Yang X, Yao Z, Guo X (2013) Wnt-mediated reciprocal regulation between cartilage and bone development during endochondral ossification. Bone 53(2):566–574. https://doi.org/10.1016/j.bone.2012.12.016CrossRef

Lerner UH, Ohlsson C (2015) The WNT system: background and its role in bone. J Intern Med 277(6):630–649. https://doi.org/10.1111/joim.12368CrossRef

10.

Joeng KS, Lee YC, Lim J, Chen Y, Jiang MM, Munivez E, Ambrose C, Lee BH (2017) Osteocyte-specific WNT1 regulates osteoblast function during bone homeostasis. J Clin Invest 127(7):2678–2688. https://doi.org/10.1172/JCI92617CrossRef

11.

Grassi F, Tyagi AM, Calvert JW, Gambari L, Walker LD, Yu M, Robinson J, Li J-Y, Lisignoli G, Vaccaro C, Adams J, Pacifici R (2016) Hydrogen sulfide is a novel regulator of bone formation implicated in the bone loss induced by estrogen deficiency. J Bone Miner Res 31:949–963. https://doi.org/10.1002/jbmr.2757CrossRef

12.

Boland GM, Perkins G, Hall DJ, Tuan RS (2004) Wnt 3a promotes proliferation and suppresses osteogenic differentiation of adult human mesenchymal stem cells. J Cell Biochem 93(6):1210–1230. https://doi.org/10.1002/jcb.20284CrossRef

13.

Shen J, Chen X, Jia H, Meyers CA, Shrestha S, Asatrian G, Ding C, Tsuei R, Zhang X, Peault B, Ting K, Soo C, James AW (2018) Effects of WNT3A and WNT16 on the osteogenic and adipogenic differentiation of perivascular stem/stromal cells. Tissue Eng Part A 24(1–2):68–80. https://doi.org/10.1089/ten.TEA.2016.0387CrossRef

14.

Hamamura K, Chen A, Nishimura A, Tanjung N, Sudo A, Yokota H (2014) Predicting and validating the pathway of Wnt3a-driven suppression of osteoclastogenesis. Cell Signal 26(11):2358–2369. https://doi.org/10.1016/j.cellsig.2014.07.018CrossRef

15.

Tu X, Joeng KS, Nakayama KI, Nakayama K, Rajagopal J, Carroll TJ, McMahon AP, Long F (2007) Noncanonical Wnt signaling through G protein-linked PKCdelta activation promotes bone formation. Dev Cell 12(1):113–127. https://doi.org/10.1016/j.devcel.2006.11.003CrossRef

16.

Qiu W, Chen L, Kassem M (2011) Activation of non-canonical Wnt/JNK pathway by Wnt3a is associated with differentiation fate determination of human bone marrow stromal (mesenchymal) stem cells. Biochem Biophys Res Commun 413(1):98–104. https://doi.org/10.1016/j.bbrc.2011.08.061CrossRef

17.

Chang J, Sonoyama W, Wang Z, Jin Q, Zhang C, Krebsbach PH, Giannobile W, Shi S, Wang CY (2007) Noncanonical Wnt-4 signaling enhances bone regeneration of mesenchymal stem cells in craniofacial defects through activation of p38 MAPK. J Biol Chem 282(42):30938–30948. https://doi.org/10.1074/jbc.M702391200CrossRef

18.

Yu B, Chang J, Liu Y, Li J, Kevork K, Al-Hezaimi K, Graves DT, Park NH, Wang CY (2014) Wnt4 signaling prevents skeletal aging and inflammation by inhibiting nuclear factor-kappaB. Nat Med 20(9):1009–1017. https://doi.org/10.1038/nm.3586CrossRef

19.

Maeda K, Kobayashi Y, Udagawa N, Uehara S, Ishihara A, Mizoguchi T, Kikuchi Y, Takada I, Kato S, Kani S, Nishita M, Marumo K, Martin TJ, Minami Y, Takahashi N (2012) Wnt5a-Ror2 signaling between osteoblast-lineage cells and osteoclast precursors enhances osteoclastogenesis. Nat Med 18(3):405–412. https://doi.org/10.1038/nm.2653CrossRef

20.

Bilkovski R, Schulte DM, Oberhauser F, Gomolka M, Udelhoven M, Hettich MM, Roth B, Heidenreich A, Gutschow C, Krone W, Laudes M (2010) Role of WNT-5a in the determination of human mesenchymal stem cells into preadipocytes. J Biol Chem 285(9):6170–6178. https://doi.org/10.1074/jbc.M109.054338CrossRef

21.

Nemoto E, Ebe Y, Kanaya S, Tsuchiya M, Nakamura T, Tamura M, Shimauchi H (2012) Wnt5a signaling is a substantial constituent in bone morphogenetic protein-2-mediated osteoblastogenesis. Biochem Biophys Res Commun 422(4):627–632. https://doi.org/10.1016/j.bbrc.2012.05.039CrossRef

22.

Takada I, Kouzmenko AP, Kato S (2009) Wnt and PPARgamma signaling in osteoblastogenesis and adipogenesis. Nat Rev Rheumatol 5(8):442–447. https://doi.org/10.1038/nrrheum.2009.137CrossRef

23.

Yang Y, Topol L, Lee H, Wu J (2003) Wnt5a and Wnt5b exhibit distinct activities in coordinating chondrocyte proliferation and differentiation. Development 130:1003–1015. https://doi.org/10.1242/dev.00324CrossRef

24.

Ling IT, Rochard L, Liao EC (2017) Distinct requirements of wls, wnt9a, wnt5b and gpc4 in regulating chondrocyte maturation and timing of endochondral ossification. Dev Biol 421(2):219–232. https://doi.org/10.1016/j.ydbio.2016.11.016CrossRef

25.

Cawthorn WP, Bree AJ, Yao Y, Du B, Hemati N, Martinez-Santibañez G, MacDougald OA (2012) Wnt6, Wnt10a and Wnt10b inhibit adipogenesis and stimulate osteoblastogenesis through a beta-catenin-dependent mechanism. Bone 50(2):477–489. https://doi.org/10.1016/j.bone.2011.08.010CrossRef

26.

Yang L, Li Q, Zhang J, Li P, An P, Wang C, Hu P, Zou X, Dou X, Zhu L (2021) Wnt7a promotes the osteogenic differentiation of human mesenchymal stem cells. Int J Mol Med 47(6):94. https://doi.org/10.3892/ijmm.2021.4927CrossRef

27.

Chen J, Tu X, Esen E, Joeng KS, Lin C, Arbeit JM, Rüegg MA, Hall MN, Ma L, Long F (2014) WNT7B promotes bone formation in part through mTORC1. PLoS Genet 10(1):e1004145. https://doi.org/10.1371/journal.pgen.1004145CrossRef

28.

Bennett CN, Longo KA, Wright WS, Suva LJ, Lane TF, Hankenson KD, MacDougald OA (2005) Regulation of osteoblastogenesis and bone mass by Wnt10b. Proc Natl Acad Sci U S A 102(9):3324–3329. https://doi.org/10.1073/pnas.0408742102CrossRef

29.

Bennett CN, Ouyang H, Ma YL, Zeng Q, Gerin I, Sousa KM, Lane TF, Krishnan V, Hankenson KD, MacDougald OA (2007) Wnt10b increases postnatal bone formation by enhancing osteoblast differentiation. J Bone Miner Res 22(12):1924–1932. https://doi.org/10.1359/jbmr.070810CrossRef

30.

Zhong Z, Zylstra-Diegel CR, Schumacher CA, Baker JJ, Carpenter AC, Rao S, Yao W, Guan M, Helms JA, Lane NE, Lang RA, Williams BO (2012) Wntless functions in mature osteoblasts to regulate bone mass. Proc Natl Acad Sci U S A 109(33):E2197-204. https://doi.org/10.1073/pnas.1120407109CrossRef

31.

Glass DA 2nd, Bialek P, Ahn JD, Starbuck M, Patel MS, Clevers H, Taketo MM, Long F, McMahon AP, Lang RA, Karsenty G (2005) Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell 8(5):751–764. https://doi.org/10.1016/j.devcel.2005.02.017CrossRef

32.

Wei W, Zeve D, Suh JM, Wang X, Du Y, Zerwekh JE, Dechow PC, Graff JM, Wan Y (2011) Biphasic and dosage-dependent regulation of osteoclastogenesis by beta-catenin. Mol Cell Biol 31(23):4706–4719. https://doi.org/10.1128/MCB.05980-11CrossRef

33.

Zhang R, Oyajobi BO, Harris SE, Chen D, Tsao C, Deng HW, Zhao M (2013) Wnt/beta-catenin signaling activates bone morphogenetic protein 2 expression in osteoblasts. Bone 52(1):145–156. https://doi.org/10.1016/j.bone.2012.09.029CrossRef

34.

Zhang M, Yan Y, Lim YB, Tang D, Xie R, Chen A, Tai P, Harris SE, Xing L, Qin YX, Chen D (2009) BMP-2 modulates beta-catenin signaling through stimulation of Lrp5 expression and inhibition of beta-TrCP expression in osteoblasts. J Cell Biochem 108(4):896–905. https://doi.org/10.1002/jcb.22319CrossRef

35.

Tang N, Song WX, Luo J, Luo X, Chen J, Sharff KA, Bi Y, He BC, Huang JY, Zhu GH, Su YX, Jiang W, Tang M, He Y, Wang Y, Chen L, Zuo GW, Shen J, Pan X, Reid RR, Luu HH, Haydon RC, He TC (2009) BMP-9-induced osteogenic differentiation of mesenchymal progenitors requires functional canonical Wnt/beta-catenin signalling. J Cell Mol Med 13(8B):2448–2464. https://doi.org/10.1111/j.1582-4934.2008.00569.xCrossRef

36.

Gao Y, Huang E, Zhang H, Wang J, Wu N, Chen X, Wang N, Wen S, Nan G, Deng F, Liao Z, Wu D, Zhang B, Zhang J, Haydon RC, Luu HH, Shi LL, He TC (2013) Crosstalk between Wnt/beta-catenin and estrogen receptor signaling synergistically promotes osteogenic differentiation of mesenchymal progenitor cells. PLoS ONE 8(12):e82436. https://doi.org/10.1371/journal.pone.0082436CrossRef

37.

Zanotti S, Smerdel-Ramoya A, Stadmeyer L, Durant D, Radtke F, Canalis E (2008) Notch inhibits osteoblast differentiation and causes osteopenia. Endocrinology 149(8):3890–3899. https://doi.org/10.1210/en.2008-0140CrossRef

38.

Rodda SJ, McMahon AP (2006) Distinct roles for Hedgehog and canonical Wnt signaling in specification, differentiation and maintenance of osteoblast progenitors. Development 133(16):3231–3244. https://doi.org/10.1242/dev.02480CrossRef

39.

Diarra D, Stolina M, Polzer K, Zwerina J, Ominsky MS, Dwyer D, Korb A, Smolen J, Hoffmann M, Scheinecker C, van der Heide D, Landewe R, Lacey D, Richards WG, Schett G (2007) Dickkopf-1 is a master regulator of joint remodeling. Nat Med 13(2):156–163. https://doi.org/10.1038/nm1538CrossRef

40.

Li S, Yin Y, Yao L, Lin Z, Sun S, Zhang J, Li X (2020) TNF-alpha treatment increases DKK1 protein levels in primary osteoblasts via upregulation of DKK1 mRNA levels and downregulation of miR-335-5p. Mol Med Rep 22(2):1017–1025. https://doi.org/10.3892/mmr.2020.11152CrossRef

41.

Rosen EY, Wexler EM, Versano R, Coppola G, Gao F, Winden KD, Oldham MC, Martens LH, Zhou P, Farese RV Jr, Geschwind DH (2011) Functional genomic analyses identify pathways dysregulated by progranulin deficiency, implicating Wnt signaling. Neuron 71(6):1030–1042. https://doi.org/10.1016/j.neuron.2011.07.021CrossRef

42.

Wang T, Xu Z (2010) miR-27 promotes osteoblast differentiation by modulating Wnt signaling. Biochem Biophys Res Commun 402(2):186–189. https://doi.org/10.1016/j.bbrc.2010.08.031CrossRef

43.

Zhang J, Tu Q, Bonewald LF, He X, Stein G, Lian J, Chen J (2011) Effects of miR-335-5p in modulating osteogenic differentiation by specifically downregulating Wnt antagonist DKK1. J Bone Miner Res 26(8):1953–1963. https://doi.org/10.1002/jbmr.377CrossRef

44.

Zhang L, Tang Y, Zhu X, Tu T, Sui L, Han Q, Yu L, Meng S, Zheng L, Valverde P, Tang J, Murray D, Zhou X, Drissi H, Dard MM, Tu Q, Chen J (2017) Overexpression of MiR-335-5p promotes bone formation and regeneration in mice. J Bone Miner Res 32(12):2466–2475. https://doi.org/10.1002/jbmr.3230CrossRef

45.

Zhang WB, Zhong WJ, Wang L (2014) A signal-amplification circuit between miR-218 and Wnt/beta-catenin signal promotes human adipose tissue-derived stem cells osteogenic differentiation. Bone 58:59–66. https://doi.org/10.1016/j.bone.2013.09.015CrossRef

46.

Melnik S, Gabler J, Dreher SI, Hecht N, Hofmann N, Großner T, Richter W (2020) MiR-218 affects hypertrophic differentiation of human mesenchymal stromal cells during chondrogenesis via targeting RUNX2, MEF2C, and COL10A1. Stem Cell Res Ther 11(1):532. https://doi.org/10.1186/s13287-020-02026-6CrossRef

47.

Zhang Z, Jiang W, Hu M, Gao R, Zhou X (2021) MiR-486-3p promotes osteogenic differentiation of BMSC by targeting CTNNBIP1 and activating the Wnt/beta-catenin pathway. Biochem Biophys Res Commun 566:59–66. https://doi.org/10.1016/j.bbrc.2021.05.098CrossRef

48.

Wei Y, Ma H, Zhou H, Yin H, Yang J, Song Y, Yang B (2021) miR-424-5p shuttled by bone marrow stem cells-derived exosomes attenuates osteogenesis via regulating WIF-mediated Wnt/beta-catenin axis. Aging (Albany NY) 13(13):17190–17201. https://doi.org/10.18632/aging.203169CrossRef

49.

Huang Y, Wan S, Yang M (2021) Circ_0067680 expedites the osteogenic differentiation of human bone marrow-derived mesenchymal stem cells through miR-4429/CTNNB1/Wnt/beta-catenin pathway. Biol Direct 16(1):16. https://doi.org/10.1186/s13062-021-00302-wCrossRef

50.

Lu Y, Liu YK, Wan FY, Shi S, Tao R (2022) CircSmg5 stimulates the osteogenic differentiation of bone marrow mesenchymal stem cells by targeting the miR-194-5p/Fzd6 axis and beta-catenin signaling. Environ Toxicol 37(3):593–602. https://doi.org/10.1002/tox.23425CrossRef

51.

Delgado-Calle J, Sato AY, Bellido T (2017) Role and mechanism of action of sclerostin in bone. Bone 96:29–37. https://doi.org/10.1016/j.bone.2016.10.007CrossRef

52.

van Bezooijen RL, ten Dijke P, Papapoulos SE, Löwik CW (2005) SOST/sclerostin, an osteocyte-derived negative regulator of bone formation. Cytokine Growth Factor Rev 16(3):319–327. https://doi.org/10.1016/j.cytogfr.2005.02.005CrossRef

53.

Sutherland MK, Geoghegan JC, Yu C, Turcott E, Skonier JE, Winkler DG (2004) Latham J. Sclerostin promotes the apoptosis of human osteoblastic cells: a novel regulation of bone formation. Bone 35(4):828–835. https://doi.org/10.1016/j.bone.2004.05.023CrossRef

54.

Ota K, Quint P, Ruan M, Pederson L, Westendorf JJ, Khosla S, Oursler MJ (2013) Sclerostin is expressed in osteoclasts from aged mice and reduces osteoclast-mediated stimulation of mineralization. J Cell Biochem 114(8):1901–1907. https://doi.org/10.1002/jcb.24537CrossRef

55.

Leupin O, Piters E, Halleux C, Hu S, Kramer I, Morvan F, Bouwmeester T, Schirle M, Bueno-Lozano M, Fuentes FJ, Itin PH, Boudin E, de Freitas F, Jennes K, Brannetti B, Charara N, Ebersbach H, Geisse S, Lu CX, Bauer A, Van Hul W, Kneissel M (2011) Bone overgrowth-associated mutations in the LRP4 gene impair sclerostin facilitator function. J Biol Chem 286(22):19489–19500. https://doi.org/10.1074/jbc.M110.190330CrossRef

56.

Levasseur R, Lacombe D, de Vernejoul MC (2005) LRP5 mutations in osteoporosis-pseudoglioma syndrome and high-bone-mass disorders. Joint Bone Spine 72(3):207–214. https://doi.org/10.1016/j.jbspin.2004.10.008CrossRef

57.

Little RD, Carulli JP, Del Mastro RG, Dupuis J, Osborne M, Folz C, Manning SP, Swain PM, Zhao SC, Eustace B, Lappe MM, Spitzer L, Zweier S, Braunschweiger K, Benchekroun Y, Hu X, Adair R, Chee L, FitzGerald MG, Tulig C, Caruso A, Tzellas N, Bawa A, Franklin B, McGuire S, Nogues X, Gong G, Allen KM, Anisowicz A, Morales AJ, Lomedico PT, Recker SM, Van Eerdewegh P, Recker RR, Johnson ML (2002) A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet 70(1):11–19. https://doi.org/10.1086/338450CrossRef

58.

Boyden LM, Mao J, Belsky J, Mitzner L, Farhi A, Mitnick MA, Wu D, Insogna K, Lifton RP (2002) High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med 346(20):1513–1521. https://doi.org/10.1056/NEJMoa013444CrossRef

59.

Van Wesenbeeck L, Cleiren E, Gram J, Beals RK, Bénichou O, Scopelliti D, Key L, Renton T, Bartels C, Gong Y, Warman ML, De Vernejoul MC, Bollerslev J, Van Hul W (2003) Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with an increased bone density. Am J Hum Genet 72(3):763–771. https://doi.org/10.1086/368277CrossRef

60.

Babij P, Zhao W, Small C, Kharode Y, Yaworsky PJ, Bouxsein ML, Reddy PS, Bodine PV, Robinson JA, Bhat B, Marzolf J, Moran RA, Bex F (2003) High bone mass in mice expressing a mutant LRP5 gene. J Bone Miner Res 18(6):960–974. https://doi.org/10.1359/jbmr.2003.18.6.960CrossRef

61.

Balemans W, Ebeling M, Patel N, Van Hul E, Olson P, Dioszegi M, Lacza C, Wuyts W, Van Den Ende J, Willems P, Paes-Alves AF, Hill S, Bueno M, Ramos FJ, Tacconi P, Dikkers FG, Stratakis C, Lindpaintner K, Vickery B, Foernzler D, Van Hul W (2001) Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet 10(5):537–543. https://doi.org/10.1093/hmg/10.5.537CrossRef

62.

Brunkow ME, Gardner JC, Van Ness J, Paeper BW, Kovacevich BR, Proll S, Skonier JE, Zhao L, Sabo PJ, Fu Y, Alisch RS, Gillett L, Colbert T, Tacconi P, Galas D, Hamersma H, Beighton P, Mulligan J (2001) Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet 68(3):577–589. https://doi.org/10.1086/318811CrossRef

63.

Li X, Ominsky MS, Niu QT, Sun N, Daugherty B, D’Agostin D, Kurahara C, Gao Y, Cao J, Gong J, Asuncion F, Barrero M, Warmington K, Dwyer D, Stolina M, Morony S, Sarosi I, Kostenuik PJ, Lacey DL, Simonet WS, Ke HZ, Paszty C (2008) Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res 23(6):860–869. https://doi.org/10.1359/jbmr.080216CrossRef

64.

Winkler DG, Sutherland MK, Geoghegan JC, Yu C, Hayes T, Skonier JE, Shpektor D, Jonas M, Kovacevich BR, Staehling-Hampton K, Appleby M, Brunkow ME, Latham JA (2003) Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J 22(23):6267–6276. https://doi.org/10.1093/emboj/cdg599CrossRef

65.

Huang Q-Y, Li GHY, Kung AWC (2009) The -9247 T/C polymorphism in the SOST upstream regulatory region that potentially affects C/EBPalpha and FOXA1 binding is associated with osteoporosis. Bone 45(2):289–294. https://doi.org/10.1016/j.bone.2009.03.676CrossRef

66.

Chang MK, Kramer I, Huber T, Kinzel B, Guth-Gundel S, Leupin O, Kneissel M (2014) Disruption of Lrp4 function by genetic deletion or pharmacological blockade increases bone mass and serum sclerostin levels. Proc Natl Acad Sci U S A 111(48):E5187–E5195. https://doi.org/10.1073/pnas.1413828111CrossRef

67.

Hamosh A, Scott AF, Amberger JS, Bocchini CA, McKusick VA (2005) Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders. Nucleic Acids Res 33:D514–D517. https://doi.org/10.1093/nar/gki033CrossRef

68.

Li X, Ominsky MS, Warmington KS, Morony S, Gong J, Cao J, Gao Y, Shalhoub V, Tipton B, Haldankar R, Chen Q, Winters A, Boone T, Geng Z, Niu QT, Ke HZ, Kostenuik PJ, Simonet WS, Lacey DL, Paszty C (2009) Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res 24(4):578–588. https://doi.org/10.1359/jbmr.081206CrossRef

69.

Li X, Warmington KS, Niu QT, Asuncion FJ, Barrero M, Grisanti M, Dwyer D, Stouch B, Thway TM, Stolina M, Ominsky MS, Kostenuik PJ, Simonet WS, Paszty C, Ke HZ (2010) Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats. J Bone Miner Res 25(12):2647–2656. https://doi.org/10.1002/jbmr.182CrossRef

70.

Ominsky MS, Vlasseros F, Jolette J, Smith SY, Stouch B, Doellgast G, Gong J, Gao Y, Cao J, Graham K, Tipton B, Cai J, Deshpande R, Zhou L, Hale MD, Lightwood DJ, Henry AJ, Popplewell AG, Moore AR, Robinson MK, Lacey DL, Simonet WS, Paszty C (2010) Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J Bone Miner Res 25(5):948–959. https://doi.org/10.1002/jbmr.14CrossRef

71.

Agholme F, Li X, Isaksson H, Ke HZ, Aspenberg P (2010) Sclerostin antibody treatment enhances metaphyseal bone healing in rats. J Bone Miner Res 25(11):2412–2418. https://doi.org/10.1002/jbmr.135CrossRef

72.

Ominsky MS, Li C, Li X, Tan HL, Lee E, Barrero M, Asuncion FJ, Dwyer D, Han CY, Vlasseros F, Samadfam R, Jolette J, Smith SY, Stolina M, Lacey DL, Simonet WS, Paszty C, Li G, Ke HZ (2011) Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones. J Bone Miner Res 26(5):1012–1021. https://doi.org/10.1002/jbmr.307CrossRef

73.

Ominsky MS, Boyd SK, Varela A, Jolette J, Felx M, Doyle N, Mellal N, Smith SY, Locher K, Buntich S, Pyrah I, Boyce RW (2017) Romosozumab improves bone mass and strength while maintaining bone quality in ovariectomized cynomolgus monkeys. J Bone Miner Res 32(4):788–801. https://doi.org/10.1002/jbmr.3036CrossRef

74.

Alharbi M, Pinto G, Finidori G, Souberbielle JC, Guillou F, Gaubicher S, Le Merrer M, Polak M (2009) Pamidronate treatment of children with moderate-to-severe osteogenesis imperfecta: a note of caution. Horm Res 71(1):38–44. https://doi.org/10.1159/000173740CrossRef

75.

Sinder BP, Eddy MM, Ominsky MS, Caird MS, Marini JC, Kozloff KM (2013) Sclerostin antibody improves skeletal parameters in a Brtl/+ mouse model of osteogenesis imperfecta. J Bone Miner Res 28(1):73–80. https://doi.org/10.1002/jbmr.1717CrossRef

76.

Sinder BP, White LE, Salemi JD, Ominsky MS, Caird MS, Marini JC, Kozloff KM (2014) Adult Brtl/+ mouse model of osteogenesis imperfecta demonstrates anabolic response to sclerostin antibody treatment with increased bone mass and strength. Osteoporos Int 25(8):2097–2107. https://doi.org/10.1007/s001CrossRef

77.

Sinder BP, Salemi JD, Ominsky MS, Caird MS, Marini JC, Kozloff KM (2015) Rapidly growing Brtl/+ mouse model of osteogenesis imperfecta improves bone mass and strength with sclerostin antibody treatment. Bone 71:115–123. https://doi.org/10.1016/j.bone.2014.10.012.98-014-2737-yCrossRef

78.

Roschger A, Roschger P, Keplingter P, Klaushofer K, Abdullah S, Kneissel M, Rauch F (2014) Effect of sclerostin antibody treatment in a mouse model of severe osteogenesis imperfecta. Bone 66:182–188. https://doi.org/10.1016/j.bone.2014.06.015CrossRef

79.

Cardinal M, Tys J, Roels T, Lafont S, Ominsky MS, Devogelaer JP, Chappard D, Mabilleau G, Ammann P, Nyssen-Behets C, Manicourt DH (2019) Sclerostin antibody reduces long bone fractures in the oim/oim model of osteogenesis imperfecta. Bone 124:137–147. https://doi.org/10.1016/j.bone.2019.04.011CrossRef

80.

Cardinal M, Dessain A, Roels T, Lafont S, Ominsky MS, Devogelaer JP, Chappard D, Mabilleau G, Ammann P, Nyssen-Behets C, Manicourt DH (2020) Sclerostin-antibody treatment decreases fracture rates in axial skeleton and improves the skeletal phenotype in growing oim/oim mice. Calcif Tissue Int 106(5):494–508. https://doi.org/10.1007/s00223-019-00655-5CrossRef

81.

Cardinal M, Chretien A, Roels T, Lafont S, Ominsky MS, Devogelaer JP, Manicourt DH, Behets C (2021) Gender-related impact of sclerostin antibody on bone in the osteogenesis imperfecta mouse. Front Genet 12:705505. https://doi.org/10.3389/fgene.2021.705505CrossRef

82.

Kedlaya R, Veera S, Horan DJ, Moss RE, Ayturk UM, Jacobsen CM, Bowen ME, Paszty C, Warman ML, Robling AG (2013) Sclerostin inhibition reverses skeletal fragility in an Lrp-deficient mouse model of OPPG syndrome. Sci Transl Med 5(211):211ra158. https://doi.org/10.1126/scitranslmed.3006627CrossRef

83.

Li X, Niu QT, Warmington KS, Asuncion FJ, Dwyer D, Grisanti M, Han CY, Stolina M, Eschenberg MJ, Kostenuik PJ, Simonet WS, Ominsky MS, Ke HZ (2014) Progressive increases in bone mass and bone strength in an ovariectomized rat model of osteoporosis after 26 weeks of treatment with a sclerostin antibody. Endocrinology 155(12):4785–4797. https://doi.org/10.1210/en.2013-1905CrossRef

84.

Gingery A, Subramaniam M, Pitel KS, Li X, Ke HZ, Turner RT, Iwaniec UT, Hawse JR (2020) Sclerostin antibody treatment rescues the osteopenic bone phenotype of TGFbeta inducible early gene-1 knockout female mice. J Cell Physiol 235(7–8):5679–5688. https://doi.org/10.1002/jcp.29500CrossRef

85.

Jacobsen CM, Barber LA, Ayturk UM, Roberts HJ, Deal LE, Schwartz MA, Weis M, Eyre D, Zurakowski D, Robling AG, Warman ML (2014) Targeting the LRP5 pathway improves bone properties in a mouse model of osteogenesis imperfecta. J Bone Miner Res 29(10):2297–2306. https://doi.org/10.1002/jbmr.2198CrossRef

86.

Grafe I, Alexander S, Yang T, Lietman C, Homan EP, Munivez E, Chen Y, Jiang MM, Bertin T, Dawson B, Asuncion F, Ke HZ, Ominsky MS, Lee B (2016) Sclerostin antibody treatment improves the bone phenotype of Crtap(-/-) mice, a model of recessive osteogenesis imperfecta. J Bone Miner Res 31(5):1030–1040. https://doi.org/10.1002/jbmr.2776CrossRef

87.

Kerschan-Schindl K (2020) Romosozumab: a novel bone anabolic treatment option for osteoporosis? Wien Med Wochenschr 170:124–131. https://doi.org/10.1007/s10354-019-00721-5CrossRef

88.

Nealy KL, Harris KB (2021) Romosozumab: a novel injectable sclerostin inhibitor with anabolic and antiresorptive effects for osteoporosis. Ann Pharmacother 55(5):677–686. https://doi.org/10.1177/1060028020952764CrossRef

89.

Lewiecki EM, Blicharski T, Goemaere S, Lippuner K, Meisner PD, Miller PD, Miyauchi A, Maddox J, Chen L, Horlait S (2018) A phase III randomized placebo-controlled trial to evaluate efficacy and safety of romosozumab in men with osteoporosis. J Clin Endocrinol Metab 103(9):3183–3193. https://doi.org/10.1210/jc.2017-02163CrossRef

90.

Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, Maddox J, Fan M, Meisner PD, Grauer A (2017) Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 377(15):1417–1427. https://doi.org/10.1056/NEJMoa1708322CrossRef

91.

Fixen C, Tunoa J (2021) Romosozumab: a review of efficacy, safety, and cardiovascular risk. Curr Osteoporos Rep 19(1):15–22. https://doi.org/10.1007/s11914-020-00652-wCrossRef

92.

Steitz SA, Speer MY, Curinga G, Yang HY, Haynes P, Aebersold R, Schinke T, Karsenty G, Giachelli CM (2001) Smooth muscle cell phenotypic transition associated with calcification: upregulation of Cbfa1 and downregulation of smooth muscle lineage markers. Circ Res 89(12):1147–1154. https://doi.org/10.1161/hh2401.101070CrossRef

93.

Zhu D, Wallace Mackenzie NC, Millán JL, Farquharson C, MacRae VE (2011) The appearance and modulation of osteocyte marker expression during calcification of vascular smooth muscle cells. PLoS ONE 6(5):e19595. https://doi.org/10.1371/journal.pone.0019595CrossRef

94.

De Maré A, Opdebeeck B, Neven E, D’Haese PC, Verhulst A (2022) Sclerostin protects against vascular calcification development in mice. J Bone Miner Res 37(4):687–699. https://doi.org/10.1002/jbmr.4503CrossRef

95.

McColm J, Hu L, Womack T, Tang CC, Chiang AY (2014) Single- and multiple-dose randomized studies of blosozumab, a monoclonal antibody against sclerostin, in healthy postmenopausal women. J Bone Miner Res 29(4):935–943. https://doi.org/10.1002/jbmr.2092CrossRef

96.

Recker RR, Benson CT, Matsumoto T, Bolognese MA, Robins DA, Alam J, Chiang AY, Hu L, Krege JH, Sowa H, Mitlak BH, Myers SL (2015) A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density. J Bone Miner Res 30(2):216–224. https://doi.org/10.1002/jbmr.2351CrossRef

97.

Appelman-Dijkstra NM, Oei HLDW, Vlug AG (2022) Winter EM (2022) Best Pract Res Clin Endocrinol Metab. In press Corrected proof available online 9:101623

98.

Glorieux FH, Devogelaer JP, Durigova M, Goemaere S, Hemsley S, Jakob F, Junker U, Ruckle J, Seefried L, Winkle PJ (2017) BPS804 anti-sclerostin antibody in adults with moderate osteogenesis imperfecta: results of a randomized phase 2a trial. J Bone Miner Res 32(7):1496–1504. https://doi.org/10.1002/jbmr.3143CrossRef

99.

Seefried L, Baumann J, Hemsley S, Hofmann C, Kunstmann E, Kiese B, Huang Y, Chivers S, Valentin MA, Borah B, Roubenoff R, Junker U, Jakob F (2017) Efficacy of anti-sclerostin monoclonal antibody BPS804 in adult patients with hypophosphatasia. J Clin Invest 127(6):2148–2158. https://doi.org/10.1172/JCI83731CrossRef

Title: Role of Wnt signaling and sclerostin in bone and as therapeutic targets in skeletal disorders
Authors: Francesca Marini
Francesca Giusti
Gaia Palmini
Maria Luisa Brandi
Publication date: 18-08-2022
Publisher: Springer London
Keywords: Osteoporosis
Osteoporosis
Osteogenesis Imperfecta
Published in: Osteoporosis International / Issue 2/2023
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-022-06523-7

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Role of Wnt signaling and sclerostin in bone and as therapeutic targets in skeletal disorders

Abstract

Summary

Introduction

Purpose and methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Summary

Introduction

Purpose and methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2023

Fracture liaison service model: project design and accreditation

Author response to the comments on our article Relatively low and moderate pre-fracture serum 25-hydroxyvitamin D levels associated with the highest survival in elderly hip fracture patients in Finland: a minimum 3-year follow-up

Appropriate dosing of burosumab in tumor-induced osteomalacia

Sarcopenia, osteoporosis, and fractures: what we see mainly depends on how we look?

Discontinuation of denosumab in men with prostate cancer

Comments on “Relatively low and moderate pre-fracture serum 25-hydroxyvitamin D levels associated with the highest survival in elderly hip fracture patients in Finland: a minimum 3-year follow-up”